eravacycline (Xerava)
Jump to navigation
Jump to search
Indications
Contraindications
- not recommended for urinary tract infections
Dosage adjustment in renal failure
- none
Pharmacokinetics
- metabolized by liver
Antimicrobial activity
- includes many highly resistant gram negatives
- some carbapenem-resistant organisms
- Acinetobacter
- MRSA
- VRE
- anaerobes
- does not cover Pseudomonas aeruginosa
Adverse effects
- gastrointestinal side effects predominate
- infusion site reactions
Mechanism of action
- tetracycline derivative, with broad antibacterial spectrum
More general terms
References
- ↑ Sax PE HIV and ID Observations. NEJM J Watch. Sept 3, 2018 https://blogs.jwatch.org/hiv-id-observations/index.php/eravacycline-approved-fda-might-used-today-future/2018/09/03/
Database
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=54726192
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=56951485
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=126970366
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=76211403
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=71463322